Drugs / GDC 695
last change Sep 2017 re-read 2 minutes ago

GDC 695

Developed for
actinic keratosis
Investigated by
Balmoral Medical company

Trials 1 · a red edge is where a trial was stopped

2017201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT02952898 Oct 2016 → Jul 2017 actinic keratosis Balmoral Medical company Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as GDC 695 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02952898
Route Topical “GDC 695 gel applied topically as directed.” NCT02952898